long intergenic non-protein coding RNA 2731Genealiases: []
Q-omics provides the consensus-scored LINC02731 profile across patient tissues and cancer cell-line models. LINC02731 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, LINC02731 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, LINC02731 RNA expression shows 14,962 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight CESC, BLCA, and TGCT as cancer lineages where LINC02731 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02731 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02731 survival associations across molecular data types. LINC02731 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02731 RNA expression–survival associations across cancer types. High LINC02731 expression shows favorable associations in CESC, LGG, LUAD, UCS, SARC and BRCA. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify CESC as the clearest survival context for LINC02731 RNA expression.
This table summarizes LINC02731 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02731. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02731 shows lower tumor expression in BLCA, THCA, KIRC, UCEC and COAD and higher tumor expression in HNSC. The BLCA box plot shows higher LINC02731 RNA expression in normal versus tumor tissue (log2 FC = −0.761, t-test p < 0.001).
This table shows molecular features associated with LINC02731 in patient tissues and cancer cell lines. In patient samples, LINC02731 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
